title: Endogenous natriuretic factors 7: biospecificity of a natriuretic gamma-tocopherol metabolite LLU-alpha.
abstract: The structural elucidation and mechanism of action of a potential component, LLU-alpha, of what is possibly a multifactorial complex known as "natriuretic hormone" was recently reported [Wechter, W.J. et al. (1996a) Proc. Natl. Acad. Sci. U.S.A. 93: 6002-6007]. "Natriuretic hormone," a long-sought factor, is believed to regulate extracellular fluid volume and consequently be pathomimetic for hypertension, cirrhosis, congestive heart failure and other volume expanded states. The studies reported herein further characterize LLU-alpha. The precursor of the endogenous LLU-alpha was demonstrated to be gamma-tocopherol by radiolabeling studies. The pharmacokinetics of infused rac-LLU-alpha proved to be biphasic (half-lives: 12 min and 6 h). Specificity of the inhibition of the 70 pS potassium channel of the thick ascending limb of the loop of Henle was examined with the natural S-enantiomer being the most potent known inhibitor whereas the analogous alpha-tocopherol metabolite, rac-5-Me-LLU-alpha, showed no inhibition. Rac-LLU-alpha does not inhibit two isozymes of the Na+/K+-ATPase. LLU-alpha is natriuretic acting via inhibition of the 70 pS potassium channel and not Na+/K+-ATPase, the assumed mechanism of action of the "natriuretic hormone." LLU-alpha, a metabolite of a vitamin, if it were found to play a role in the regulation of extracellular fluid volume, would be the second example of a vitamin acting as a precursor for a hormone. Of considerable interest is the fact that this manuscript reports the first biological activity of gamma-tocopherol, a member of the vitamin E complex.
authors.affiliation: Laboratory of Chemical Endocrinology, Loma Linda University School of Medicine, California 92350, USA.
authors.forename: E D
authors.initials: ED
authors.lastname: Murray
authors.forename: W J
authors.initials: WJ
authors.lastname: Wechter
authors.forename: D
authors.initials: D
authors.lastname: Kantoci
authors.forename: W H
authors.initials: WH
authors.lastname: Wang
authors.forename: T
authors.initials: T
authors.lastname: Pham
authors.forename: D D
authors.initials: DD
authors.lastname: Quiggle
authors.forename: K M
authors.initials: KM
authors.lastname: Gibson
authors.forename: D
authors.initials: D
authors.lastname: Leipold
authors.forename: B M
authors.initials: BM
authors.lastname: Anner
mesh_terms: D000818:Animals; D001665:Binding Sites; D002839:Chromans / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D009318:Natriuresis / Q000502:physiology*; D026902:Potassium Channel Blockers; D011422:Propionates / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D000254:Sodium-Potassium-Exchanging ATPase / Q000037:antagonists & inhibitors; D013237:Stereoisomerism; D014810:Vitamin E / Q000378:metabolism* / Q000494:pharmacology
chemical_list: D002839:Chromans; D026902:Potassium Channel Blockers; D011422:Propionates; D014810:Vitamin E; C107690:2,7,8-trimethyl-2-(beta-carboxyethyl)-6-hydroxychroman; D000254:Sodium-Potassium-Exchanging ATPase